Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Beloranib

An Efficacy, Safety and Pharmacokinetics Study of Beloranib (ZGN-440 for Injectable Suspension) in Obese Subjects

Zafgen · Phase 2 · Completed · Enrollment 160

NCT01666691

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Placebon/rn/rn/rn/r
0.3 mg Beloranibn/rn/rn/rn/r
0.6 mg Beloranibn/rn/rn/rn/r
1.2 mg Beloranibn/rn/rn/rn/r
2.4 mg Beloranibn/rn/rn/rn/r
3.2 mg Beloranibn/rn/rn/rn/r

Not shown

  • Placebo: endpoint not reported
  • 0.3 mg Beloranib: endpoint not reported
  • 0.6 mg Beloranib: endpoint not reported
  • 1.2 mg Beloranib: endpoint not reported
  • 2.4 mg Beloranib: endpoint not reported
  • 3.2 mg Beloranib: endpoint not reported